Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The role of surgery and chemotherapy for stage IV small bowel adenocarcinoma (SBA) is still confused. The results from previous analyses have been limited by small sample sizes and different treatment regimens.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Patients with stage IV SBA were identified in the Surveillance, Epidemiology, and End Result Program (SEER) database. Cause‐specific survival (CSS) and overall survival (OS) were calculated with Kaplan‐Meier methods and log‐rank test. Multiple logistic and Cox regression identified covariates associated with treatment options and survival.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>1219 eligible patients were involved in this study. The median age was 67 (range, 20‐95) with 655 (53.7%) males and 564 (46.3%) females. Age and primary tumor site were significantly associated with surgery performance, age was also significantly associated with chemotherapy (<i>P </i>< .01). To reduce bias, further six subgroups were divided by age (≤65 and >65) and primary tumor site (duodenum, jejunum and ileum). Chemotherapy and surgery conferred a benefit on survival of the whole cohort (the median CSS of different treatment groups were 17, 9, 4, and 1 month respectively, <i>P </i>< .001) and most subgroups (83.3%, 5/6). In multivariate analysis, surgery (<i>P </i>= .006), and chemotherapy (<i>P </i>= .038) are still independent factors of favorable CSS and OS. For patients with surgery (n = 362), radical surgery was not associated with better survival. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>For stage IV SBA patients, the present study showed that age and primary tumor site were significantly associated with treatment preference. Surgery and chemotherapy were consistently correlated with favorable survival for the whole cohort or most specific subgroups. However, compared with palliative surgery, significant association was not found in patients with radical surgery with better outcome. More prospective well‐defined cohorts would add knowledge for this rare disease.</p></section>

Clinical features and the efficacy of adjuvant chemotherapy in resectable small bowel adenocarcinoma: a single-center, long-term analysis

Risk and Prognostic Factors for Small Bowel Adenocarcinoma: A Multicenter Retrospective Observational Study in China

Retrospective Analysis of 119 Small Bowel Adenocarcinoma in Chinese Patients

Efficacy of surgery and chemotherapy for stage IV small bowel adenocarcinoma: A population‐based analysis using Surveillance, Epidemiology, and End Result Program database

Prognostic Similarities Between Gastric Adenosquamous Carcinoma and Typical Gastric Adenocarcinoma: A Large Population-Based and Propensity Score-Matched Study.

Clinical analysis of 55 cases of primary small bowel adenocarcinoma

Clinical features, treatment, and prognosis of different histological types of primary small bowel adenocarcinoma: A propensity score matching analysis based on the SEER database

Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study

Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma

Safety and Effectiveness of Neoadjuvant Immunotherapy Combined with Chemotherapy Followed by Surgical Resection in Patients with Stage I-IIIA Small-Cell Lung Cancer: a Retrospective Single-Arm Clinical Trial.

Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database

Primary small intestinal malignant tumors: survival analysis of 48 postoperative patients.

Impact of Adjuvant Therapy on Survival in Surgically Resected Limited-Stage Small Cell Lung Cancer

The Role of Adjuvant Chemotherapy in Early-Stage Combined Small-Cell Lung Cancer

Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in small bowel adenocarcinomas

Incidence, clinical management and prognosis of patients with small intestinal adenocarcinomas from 1999 through 2019: a nationwide Dutch cohort study

Molecular characterization of Chinese patients with small bowel adenocarcinoma

Relationship Between Immunophenotypes, Genetic Profiles, and Clinicopathologic Characteristics in Small Bowel Adenocarcinoma

Long-term Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Esophagectomy Following Neoadjuvant Chemotherapy: a Cohort Study

Clinical Features And Outcomes Analysis Of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy

The Clinical Role of Adjuvant Chemotherapy after Sublobar Resection for Non-Small-Cell Lung Cancer ≤ 20 mm with Lymph Node Metastases: A Propensity-Matched Analysis of the National Cancer Database